Targeted Adenoviral Vectors III

Transcriptional Targeting

Sudhanshu P. Raikwar, Chinghai Kao, Thomas Gardner

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Gene therapy is an innovative approach aimed to introducing genetic material into an organism for therapeutic intent. Still in its infancy, this novel concept has witnessed a fundamental preclinical success with numerous ongoing clinical trials to confirm these findings. Critical to the success of gene therapy trials are issues relating to specific delivery of physiologically active biomolecules at therapeutically significant concentrations. Initially this was achieved by using direct intralesional injections of vectors to localize the delivery to the target tissue and universal promoters to maximized expression at that site. Over the past several years we and several other investigators have investigated the potential of tumor-specific promoters to transcriptionally regulate gene expression in the laboratory and in clinical trials. The safety demonstrated by these trials using tumor/tissue-specific promoters has led to the recent approval of a trial administering a conditionally replicative adenovirus systemically for the treatment of metastatic prostate cancer.

Original languageEnglish (US)
Title of host publicationAdenoviral Vectors for Gene Therapy: Second Edition
PublisherElsevier Inc.
Pages259-292
Number of pages34
ISBN (Print)9780128002766
DOIs
StatePublished - Apr 6 2016

Fingerprint

Gene therapy
Genetic Therapy
Tumors
Clinical Trials
Intralesional Injections
Tissue
Direct injection
Biomolecules
Adenoviridae
Gene expression
Carcinogens
Prostatic Neoplasms
Research Personnel
Safety
Gene Expression
Therapeutics
Genes
Neoplasms

Keywords

  • Oncolysis
  • Transcription
  • Transcriptional targeting
  • Tumor-specific promoters

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Raikwar, S. P., Kao, C., & Gardner, T. (2016). Targeted Adenoviral Vectors III: Transcriptional Targeting. In Adenoviral Vectors for Gene Therapy: Second Edition (pp. 259-292). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-800276-6.00010-3

Targeted Adenoviral Vectors III : Transcriptional Targeting. / Raikwar, Sudhanshu P.; Kao, Chinghai; Gardner, Thomas.

Adenoviral Vectors for Gene Therapy: Second Edition. Elsevier Inc., 2016. p. 259-292.

Research output: Chapter in Book/Report/Conference proceedingChapter

Raikwar, SP, Kao, C & Gardner, T 2016, Targeted Adenoviral Vectors III: Transcriptional Targeting. in Adenoviral Vectors for Gene Therapy: Second Edition. Elsevier Inc., pp. 259-292. https://doi.org/10.1016/B978-0-12-800276-6.00010-3
Raikwar SP, Kao C, Gardner T. Targeted Adenoviral Vectors III: Transcriptional Targeting. In Adenoviral Vectors for Gene Therapy: Second Edition. Elsevier Inc. 2016. p. 259-292 https://doi.org/10.1016/B978-0-12-800276-6.00010-3
Raikwar, Sudhanshu P. ; Kao, Chinghai ; Gardner, Thomas. / Targeted Adenoviral Vectors III : Transcriptional Targeting. Adenoviral Vectors for Gene Therapy: Second Edition. Elsevier Inc., 2016. pp. 259-292
@inbook{a3b08f81e0b54fb6860964cb3661bc7e,
title = "Targeted Adenoviral Vectors III: Transcriptional Targeting",
abstract = "Gene therapy is an innovative approach aimed to introducing genetic material into an organism for therapeutic intent. Still in its infancy, this novel concept has witnessed a fundamental preclinical success with numerous ongoing clinical trials to confirm these findings. Critical to the success of gene therapy trials are issues relating to specific delivery of physiologically active biomolecules at therapeutically significant concentrations. Initially this was achieved by using direct intralesional injections of vectors to localize the delivery to the target tissue and universal promoters to maximized expression at that site. Over the past several years we and several other investigators have investigated the potential of tumor-specific promoters to transcriptionally regulate gene expression in the laboratory and in clinical trials. The safety demonstrated by these trials using tumor/tissue-specific promoters has led to the recent approval of a trial administering a conditionally replicative adenovirus systemically for the treatment of metastatic prostate cancer.",
keywords = "Oncolysis, Transcription, Transcriptional targeting, Tumor-specific promoters",
author = "Raikwar, {Sudhanshu P.} and Chinghai Kao and Thomas Gardner",
year = "2016",
month = "4",
day = "6",
doi = "10.1016/B978-0-12-800276-6.00010-3",
language = "English (US)",
isbn = "9780128002766",
pages = "259--292",
booktitle = "Adenoviral Vectors for Gene Therapy: Second Edition",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Targeted Adenoviral Vectors III

T2 - Transcriptional Targeting

AU - Raikwar, Sudhanshu P.

AU - Kao, Chinghai

AU - Gardner, Thomas

PY - 2016/4/6

Y1 - 2016/4/6

N2 - Gene therapy is an innovative approach aimed to introducing genetic material into an organism for therapeutic intent. Still in its infancy, this novel concept has witnessed a fundamental preclinical success with numerous ongoing clinical trials to confirm these findings. Critical to the success of gene therapy trials are issues relating to specific delivery of physiologically active biomolecules at therapeutically significant concentrations. Initially this was achieved by using direct intralesional injections of vectors to localize the delivery to the target tissue and universal promoters to maximized expression at that site. Over the past several years we and several other investigators have investigated the potential of tumor-specific promoters to transcriptionally regulate gene expression in the laboratory and in clinical trials. The safety demonstrated by these trials using tumor/tissue-specific promoters has led to the recent approval of a trial administering a conditionally replicative adenovirus systemically for the treatment of metastatic prostate cancer.

AB - Gene therapy is an innovative approach aimed to introducing genetic material into an organism for therapeutic intent. Still in its infancy, this novel concept has witnessed a fundamental preclinical success with numerous ongoing clinical trials to confirm these findings. Critical to the success of gene therapy trials are issues relating to specific delivery of physiologically active biomolecules at therapeutically significant concentrations. Initially this was achieved by using direct intralesional injections of vectors to localize the delivery to the target tissue and universal promoters to maximized expression at that site. Over the past several years we and several other investigators have investigated the potential of tumor-specific promoters to transcriptionally regulate gene expression in the laboratory and in clinical trials. The safety demonstrated by these trials using tumor/tissue-specific promoters has led to the recent approval of a trial administering a conditionally replicative adenovirus systemically for the treatment of metastatic prostate cancer.

KW - Oncolysis

KW - Transcription

KW - Transcriptional targeting

KW - Tumor-specific promoters

UR - http://www.scopus.com/inward/record.url?scp=84969700050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969700050&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-800276-6.00010-3

DO - 10.1016/B978-0-12-800276-6.00010-3

M3 - Chapter

SN - 9780128002766

SP - 259

EP - 292

BT - Adenoviral Vectors for Gene Therapy: Second Edition

PB - Elsevier Inc.

ER -